Osteonecrosis of the jaw (MRONJ) is associated with the consequences of taking antiresorptive or antiangiogenic medicine for bone metastases or osteoporosis. MRONJ is characterized by open necrotic bone in the maxillofacial area that lasts more than eight weeks. The management of such a condition depends on several factors, among which the choice of MRONJ therapeutic method is considered to be the leading one. However, to date, no specific treatment with a uniform standard of treatment has been established. The purpose of this article is to present the outcome of surgical treatment of MRONJ with the addition of platelet-rich fibrin (PRF). A case of a woman with Medication-related osteonecrosis of the lower jaw, whose condition was monitored for a period of two years, is presented.